Cover Image
市場調查報告書

骨質疏鬆症的全球市場 (2016-2026年):骨吸收抑製藥、蛋白融化藥、其他藥劑的收益預測

Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others

出版商 Visiongain Ltd 商品編碼 302716
出版日期 內容資訊 英文 207 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
骨質疏鬆症的全球市場 (2016-2026年):骨吸收抑製藥、蛋白融化藥、其他藥劑的收益預測 Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others
出版日期: 2016年04月04日 內容資訊: 英文 207 Pages
簡介

本報告提供全球骨質疏鬆症治療藥的市場調查,骨質疏鬆症及其治療概要,整體市場及各類藥物的市場規模的變化與預測,市場成長的各種影響因素分析,領導品牌的收益規模的變化與預測,開發平台簡介,各主要國家的市場背景、市場趨勢、市場規模變化與預測,主要企業簡介,各種定性分析,專家的採訪等彙整資料。

第1章 報告概要

第2章 骨質疏鬆症:簡介

  • 骨質疏鬆症的盛行率、發病率
  • 骨質疏鬆症:無聲殺手
  • 在骨折治癒中重要的骨芽細胞
  • 骨質疏鬆症的分類:各類型
  • 骨質疏鬆症的分類:各治療
  • 骨質疏鬆症的風險因素

第3章 全球市場的預測

  • 市場實際成果
  • 市場預測
  • 市場預測:各類藥物
    • 骨吸收抑製藥
    • 蛋白融化藥
    • 其他
  • 市場促進因素、阻礙要素

第4章 骨質疏鬆症治療藥的收益預測

  • 雙膦酸鹽
    • Merck (MSD的)Fosamax (Alendronate)
    • Roche的Bonviva/Boniva (Ibandronate)
    • Sanofi的Actonel/Atelvia (Risedronate)
    • Novartis的Reclast/Aclasta (Zoledronate)
    • 小野藥品工業、Astellas的Recalbon/Bonoteo (Minodronate)
  • SERM
    • Eli Lilly的Evista (Raloxifene)
    • Pfizer的Duavee
  • 抗RANKL抗體
    • Amgen的Prolia (Denosumab)
  • 副甲狀腺素 (PTH)
    • Eli Lilly的Forteo (Teriparatide)
  • 其他
    • Servier的Protelos (Strontium Ranelate)

第5章 開發平台藥物簡介

  • Merck (MSD的)Odanacatib (MK 0822)
  • Amgen的Romosozumab (AMG 785)
  • Blosozumab (LY2541546)
  • Radius Health的Abaloparatide (BA-058)
  • ZP-PTH: Parathyroid

第6章 各國市場預測

  • 全球市場的實際成果、預測:各地區
  • 美國
  • 歐盟5國
  • 日本
  • 金磚四國
  • 韓國
  • 其他地區
  • 各國市場相關考察

第7章 主要企業的預測

  • 目前市場領導
  • Eli Lilly
  • Amgen
  • UCB
  • GSK
  • Merck and Co. (MSD)
  • Allergan
  • Sanofi
  • Pfizer
  • Novartis
  • Radius Health

第8章 定性分析

  • SWOT分析
  • STEP分析

第9章 調查採訪

第10章 總論

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0105

Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others - our new study reveals trends, R&D progress, and predicted revenues

Where is the Osteoporosis Drugs market heading? Visiongain's report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 207 page report provides 140 charts. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Osteoporosis Drugs market.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
  • Read full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
    • Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF
    • Interview with Paul Mitchell, founder of Synthesis Medical, an independent healthcare consultancy
    • Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist at Pursuit Physical Therapy

image1

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets: Antiresorptive drugs, Anabolic drugs and Others. These submarkets are further broken down into bisphosphonates, selective oestrogen receptor modulators, RANKL antibodies and the parathyroid hormones.

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products' sales - what's possible for those Osteoporosis Drugs?

How will individual osteoporosis drugs perform from 2016 to 2026 at world level? Our study forecasts revenues of these 13 brands:

  • 1. Fosamax
  • 2. Boniva/Bonviva
  • 3. Actonel/Atelvia
  • 4. Reclast/Aclasta
  • 5. Recalbon/Bonoteo
  • 6. Evista
  • 7. Duavee
  • 8. Prolia
  • 9. Forteo
  • 10. Odanacatib
  • 11. Romosozumab
  • 12. Protelos
  • 13. Abaloparatide

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?

You will discover individual revenue forecasts for 12 leading national markets from 2016-2026:

  • United States (US)
  • Japan
  • Germany, France, the UK, Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).
  • South Korea

image2

Leading companies and the potential for market growth

You can also see which companies hold the most potential:

  • Eli Lilly
  • Amgen
  • UCB
  • GSK
  • MSD
  • Allergan
  • Sanofi
  • Pfizer
  • Novartis
  • Radius Health

Research and development - assess innovation, trends and possibilities

Our report discusses R&D, appraising technological, clinical and commercial possibilities.

Our report forecasts prominent pipeline drugs and discusses their submarkets. 3 drugs are forecasted in this chapter with other promising drugs discussed. New submarkets are also introduced; the anti-sclerostin monoclonal antibodies and the cathepsin K inhibitors.

How the Osteoporosis Drugs Market report helps you

Our new report discusses issues and events affecting the osteoporosis market. You will find quantitative and qualitative analyses on:

  • Revenue to 2026 for the global osteoporosis drugs market - discover the sales potential of that industry
  • Revenues to 2026 for the osteoporosis submarkets - find sales predictions for top treatments, seeing how they can compete and succeed
  • Revenue forecasts to 2026 for 13 individual osteoporosis drugs - find the current best selling osteoporosis drug and how this will change over the next 10 years
  • Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia - discover the best countries and regions for commercial expansion
  • Activities of established, rising and emerging companies - hear about firms' products, capabilities, advances and outlooks, also with industry opinions
  • Discussions of R&D - investigate progress in that industry, finding technological, clinical and commercial outlooks and opportunities
  • Analysis of what stimulates and restrains the osteoporosis market - assess challenges and strengths for those medicines, their developers, producers and sellers, helping you compete and stay ahead.
  • Patent expiries and how they will affect the market.
  • The challenges facing the market, including the entry of generics on the market.
  • How unmet medical needs will fuel growth in emerging markets over the next 10 years
  • How next generation therapies will come to dominate the market by the end of the forecast.

Table of Contents

1. Report Overview

  • 1.1 Overview of the Osteoporosis Industry and Market 2016-2026
  • 1.2 Why You should Read this Report
  • 1.3 How this Study Delivers
  • 1.4 Main Questions Answered by this Report
  • 1.5 Who is this Investigation for?
  • 1.6 Method of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associated Reports
  • 1.9 About visiongain

2. Introduction to Osteoporosis

  • 2.1 Osteoporosis Prevalence and Incidence in 2015
  • 2.2 Osteoporosis: The Silent Killer
  • 2.3 Osteoblasts are Critical in Bone Healing
  • 2.4 Classifying Osteoporosis by Types
  • 2.5 Classifying Osteoporosis by Treatments
    • 2.5.1 Antiresorptive Medication
    • 2.5.2 Anabolic Medication
  • 2.6 Osteoporosis Risk Factors

3. Global Forecast for the Osteoporosis Market 2016-2026

  • 3.1 The Global Osteoporosis Drug Market in 2015
  • 3.2 The Global Osteoporosis Drug Market Forecast, 2016-2026
  • 3.3 The Global Osteoporosis Market by Main Therapeutic Class, 2016-2026
    • 3.3.1 The Antiresorptive Drug Submarket
      • 3.3.1.1 Antiresorptive Drug Submarket Forecast 2016-2026
    • 3.3.2 The Anabolic Drug Submarket
    • 3.3.2.1 Anabolic Drug Submarket Forecast 2016-2026
    • 3.3.3 The Others Submarket
    • 3.3.3.1 The Others Submarket Forecast 2016-2026
  • 3.4 Drivers and Restraints for the Global Osteoporosis Market 2016-2026

4. Individual Osteoporosis Drug Revenue Forecasts 2016-2026

  • 4.1 The Bisphosphonates Submarket
    • 4.1.1 The Bisphosphonates Revenue Forecast, 2016-2026
    • 4.1.2 Merck (MSD)'s Fosamax (Alendronate)
      • 4.1.2.1 Generic Competition for Fosamax in 2016
      • 4.1.2.2 Fosamax Market Forecast 2016-2026
    • 4.1.3 Roche's Bonviva/Boniva (Ibandronate)
      • 4.1.3.1 Boniva/Bonviva Market Forecast 2016-2026
    • 4.1.4 Sanofi's Actonel/Atelvia (Risedronate)
      • 4.1.4.1 Actonel/Atelvia Market Forecast 2016-2026
    • 4.1.5 Novartis' Reclast/Aclasta (Zoledronate)
      • 4.1.5.1 Reclast/Aclasta (Zoledronate) in the Leading National Markets, 2016
      • 4.1.5.2 Generic Competition for Reclast/Aclasta (Zoledronate), 2016
      • 4.1.5.3 Reclast/Aclasta (Zoledronate) Market Forecast 2016-2026
    • 4.1.6 Ono Pharmaceutical's/Astellas' Recalbon/Bonoteo (Minodronate)
      • 4.1.6.1 Recalbon/Bonoteo Market Forecast, 2016-2026
  • 4.2 The SERMs Submarket
    • 4.2.1 The SERMs Revenue Forecast, 2016-2026
    • 4.2.2 Eli Lilly's Evista (Raloxifene)
      • 4.2.2.1 Generic Raloxifene Slashes Evista Profits
      • 4.2.2.2 Evista Market Forecast 2016-2026
    • 4.2.3 Pfizer's Duavee
      • 4.2.3.1 Duavee Market Forecast 2016-2026
  • 4.3 The Global RANKL Antibody Market Forecast, 2016-2026
    • 4.3.1 Amgen's Prolia (Denosumab)
      • 4.3.1.1 History of Prolia (Denosumab)
      • 4.3.1.2 Prolia (Denosumab) Market Forecast 2016-2026
  • 4.4 The Parathyroid Hormone Submarket
    • 4.4.1 Parathyroid Hormone Submarket Forecast 2016-2026
    • 4.4.2 Eli Lilly's Forteo (Teriparatide)
    • 4.4.3 Forteo Market Forecast 2016-2026
    • 4.4.4 Preotact/Preos Withdrawn from the Market
  • 4.5 The Others Submarket
    • 4.5.1 The Others Submarket Forecast 2016-2026
    • 4.5.2 Servier's Protelos (Strontium Ranelate) 2016-2026
    • 4.5.3 Protelos Market Forecast 2016-2026

5. Pipeline Drugs for the Osteoporosis Market 2016-2026

  • 5.1 Merck (MSD)'s Odanacatib (MK 0822)
    • 5.1.1 Odanacatib Market Forecast 2016-2026
  • 5.2 Amgen's Romosozumab (AMG 785)
    • 5.2.1 Romosozumab Market Forecast 2016-2026
  • 5.3 Blosozumab (LY2541546)
  • 5.4 Radius Health's Abaloparatide (BA-058)
    • 5.4.1 Abaloparatide Market Forecast 2016-2026
  • 5.5 ZP-PTH: Parathyroid
    • 5.6 ZT-034: Will Need More Than Biomarkers for Approval

6. National Submarkets for the Osteoporosis Market 2016-2026

  • 6.1 The Global Osteoporosis Market by Regional Breakdown, 2015, 2020 and 2026
  • 6.2 The Global Osteoporosis Market Forecast by Regional Breakdown, 2015, 2020 and 2026
  • 6.3 The US Osteoporosis Drug Market, 2015
    • 6.3.1 The US Osteoporosis Market Forecast, 2016-2026
    • 6.3.2 The Reimbursement System of the US
    • 6.3.3 The US Must Improve Osteoporosis Preventation Measures
    • 6.3.4 Drivers and Restraints for the US Osteoporosis Market, 2016-2026
  • 6.4 The EU5 Osteoporosis Osteoporosis Market Forecasts, 2016-2026
    • 6.4.1 The German Osteoporosis Market Forecast, 2016-2026
    • 6.4.2 The French Osteoporosis Market Forecast, 2016-2026
    • 6.4.3 The UK Osteoporosis Drug Market Forecast, 2016-2026
    • 6.4.4 The Italian Osteoporosis Market Forecast, 2016-2026
    • 6.4.5 The Spanish Osteoporosis Market Forecast, 2016-2026
  • 6.5 The Japanese Osteoporosis Drug Market, 2015
    • 6.5.1 The Japanese Osteoporosis Market Forecast, 2016-2026
    • 6.5.2 Recent Trends in the Japanese Osteoporosis Market
  • 6.6 The BRIC Countries Osteoporosis Market, 2015
    • 6.6.1 The BRIC Countries Osteoporosis Market Forecast, 2016-2026
    • 6.6.2 The Chinese Osteoporosis Market Forecast, 2016-2026
      • 6.6.2.1 Drivers of Growth in the Chinese Market
    • 6.6.3 The Indian Osteoporosis Market Forecast, 2016-2026
    • 6.6.4 The Russian Osteoporosis Market Forecast, 2016-2026
    • 6.6.5 The Brazilian Osteoporosis Market Forecast, 2016-2026
  • 6.7 The South Korean Osteoporosis Market, 2016-2026
  • 6.8 The Osteoporosis Market for the Rest of the World, 2016-2026
  • 6.9 Additional Considerations for the National Osteoporosis Markets

7. Market Leaders for the Osteoporosis Market 2016-2026

  • 7.1 Market Leaders in 2015
  • 7.2 Eli Lilly
    • 7.2.1 Eli Lilly Osteoporosis Drug Sales Forecast, 2016-2026
  • 7.3 Amgen
    • 7.3.1 Amgen: Reacquires All Rights for Prolia from GSK
    • 7.3.2 Amgen Osteoporosis Drug Sales Forecast, 2016-2026
  • 7.4 UCB
    • 7.4.1 UCB Osteoporosis Drug Sales Forecast, 2016-2026
  • 7.5 GSK
  • 7.6 Merck and Co. (MSD)
    • 7.6.1 Merck (MSD) Osteoporosis Drug Sales Forecast, 2016-2026
  • 7.7 Allergan
  • 7.8 Sanofi
  • 7.9 Pfizer
  • 7.10 Novartis
  • 7.11 Radius Health

8. Qualitative Analysis of the Osteoporosis Market

  • 8.1 SWOT (Strengths, Weaknesses, Opportunities and Threats) Analysis of the Osteoporosis Market, 2016-2026
  • 8.2 STEP (Social, Technological, Economic and Political) Analysis of the Osteoporosis Market, 2016-2026

9. Research Interviews

  • 9.1 Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF
    • 9.1.1 On the Problem of Osteoporosis in Today's Society
    • 9.1.2 On the Work of the National Osteoporosis Foundation
    • 9.1.3 On Drug Treatments and the Prevention of Osteoporosis
  • 9.2 Interview with Paul Mitchell, Founder of Synthesis Medical Limited
    • 9.2.1 On the Work of Synthesis Medical
    • 9.2.2 On the Burden of Osteoporosis to Society
    • 9.2.3 On Education and Policy for Osteoporosis
    • 9.2.4 On Primary and Secondary Fractures
    • 9.2.5 On Drug Treatments and Innovation for Osteoporosis
  • 9.3 Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist, Pursuit Physical Therapy
    • 9.3.1 On the Therapy used at Pursuit Physical Therapy
    • 9.3.2 On Primary and Secondary Fractures
    • 9.3.3 On Education and Innovation for Osteoporosis

10. Conclusions

  • 10.1 The Global Osteoporosis Market and Submarkets in 2015
  • 10.2 The Global Osteoporosis Market and Submarkets until 2026
  • 10.3 The National Markets for Osteoporosis in 2015
  • 10.4 The National Markets for Osteoporosis until 2026
  • 10.5 Leading Companies in the Osteoporosis Market
  • 10.6 Drivers for the Osteoporosis Market
  • 10.7 Challenges to Overcome for the Future Osteoporosis Drug Market
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 2.1 Mechanisms Involved in Bone Grafting
  • Table 3.1 Treatments for Osteoporosis, by Therapeutic Classes, Drug Category and Branded Drugs, 2016
  • Table 3.2 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
  • Table 3.3 The Global Osteoporosis Drug Market: Revenue ($m) and Market Shares (%) by Therapeutic Classes, 2015, 2020 and 2026
  • Table 3.4 The Global Antiresorptive Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
  • Table 3.5 The Global Anabolic Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
  • Table 3.6 The Others Submarket Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
  • Table 4.1 The Bisphosphonates Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.2 Fosamax Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.3 Boniva/Bonviva Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.4 Actonel/Atelvia Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.5 Reclast/Aclasta Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.6 Recalbon/Bonoteo Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.7 The SERMs Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.8 Evista Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.9 Duavee Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.10 Prolia Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.11 The PTH Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.12 Forteo Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.13 The Others Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.14 Protelos Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 5.1 Odanacatib Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 5.2 Romosozumab Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 5.3 Abaloparatide Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 6.1 The Global Osteoporosis Drug Market: Revenue ($m) by Leading Regional Markets, 2015, 2020 and 2026
  • Table 6.2 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2015, 2020 and 2026
  • Table 6.3 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.4 The US Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.5 The EU5 Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.6 The Median Ages in EU5 Nations from 1960 to 2060, by Country
  • Table 6.7 Germany Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.8 France Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.9 UK Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.10 Italy Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.11 Spain Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.12 Japan Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.13 The BRIC Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.14 China Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.15 India Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.16 Russia Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.17 Brazil Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.18 South Korea Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.19 RoW Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 7.1 The Eli Lilly Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.2 The Amgen Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.3 The UCB Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.4 The Merck (MSD) Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.5 The Sanofi Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.6 The Pfizer Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.7 The Novartis Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.8 The Radius Health Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 8.1 Strengths and Weaknesses of the Osteoporosis Market, 2016-2026
  • Table 8.2 Opportunities and Threats to the Osteoporosis Market, 2016-2026
  • Table 8.3 Social and Technological Factors of the Osteoporosis Market, 2016-2026
  • Table 8.4 Economic and Political Factors of the Osteoporosis Market, 2016-2026

List of Figures

  • Figure 1.1 Global Osteoporosis Drug Market Segmentation
  • Figure 3.1 The Global Osteoporosis Drug Market Revenue ($m) Forecast, 2016-2026
  • Figure 3.2 The Global Osteoporosis Drug Market AGR (%) Forecast, 2016-2026
  • Figure 3.3 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2015
  • Figure 3.4 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2020
  • Figure 3.5 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2026
  • Figure 3.6 Drivers and Restraints for the Osteoporosis Market, 2016-2026
  • Figure 4.1 The Bisphosphonates Revenue Forecast ($m), 2016-2026
  • Figure 4.2 The Bisphosphosphonates Drug Market AGR (%) Forecast, 2016-2026
  • Figure 4.3 Fosamax Revenue Forecast ($m), 2016-2026
  • Figure 4.4 Fosamax AGR (%) Forecast, 2016-2026
  • Figure 4.5 Boniva/Bonviva Revenue Forecast ($m), 2016-2026
  • Figure 4.6 Boniva/Bonviva AGR (%) Forecast, 2016-2026
  • Figure 4.7 Actonel/Ateliva Revenue Forecast ($m), 2016-2026
  • Figure 4.8 Actonel/Ateliva AGR (%) Forecast, 2016-2026
  • Figure 4.9 Reclast/Aclasta Revenue Forecast ($m), 2016-2026
  • Figure 4.10 Reclast/Aclasta AGR (%) Forecast, 2016-2026
  • Figure 4.11 Recalbon/Bonoteo Revenue Forecast ($m), 2016-2026
  • Figure 4.12 Recalbon/Bonoteo AGR (%) Forecast, 2016-2026
  • Figure 4.13 The SERMs Revenue Forecast ($m), 2016-2026
  • Figure 4.14 The SERMs AGR (%) Forecast, 2016-2026
  • Figure 4.15 Evista Revenue Forecast ($m), 2016-2026
  • Figure 4.16 Evista AGR (%) Forecast, 2016-2026
  • Figure 4.17 Duavee Revenue Forecast ($m), 2016-2026
  • Figure 4.18 Duavee AGR (%) Forecast, 2016-2026
  • Figure 4.19 Prolia Revenue Forecast ($m), 2016-2026
  • Figure 4.20 Prolia AGR (%) Forecast, 2016-2026
  • Figure 4.21 PTH Revenue Forecast ($m), 2016-2026
  • Figure 4.22 PTH AGR (%) Forecast, 2016-2026
  • Figure 4.23 Forteo Revenue Forecast ($m), 2016-2026
  • Figure 4.24 Forteo AGR (%) Forecast, 2016-2026
  • Figure 4.25 The Others Submarket Revenue Forecast ($m), 2016-2026
  • Figure 4.26 The Others Submarket AGR (%) Forecast, 2016-2026
  • Figure 4.27 Protelos Revenue Forecast ($m), 2016-2026
  • Figure 4.28 Protelos Submarket AGR (%) Forecast, 2016-2026
  • Figure 5.1 Odanacatib Revenue Forecast ($m), 2016-2026
  • Figure 5.2 Odanacatib Submarket AGR (%) Forecast, 2017-2026
  • Figure 5.3 Romosozumab Revenue Forecast ($m), 2016-2026
  • Figure 5.4 Romosozumab Submarket AGR (%) Forecast, 2017-2026
  • Figure 5.5 Abaloparatide Revenue Forecast ($m), 2016-2026
  • Figure 5.6 Abaloparatide Submarket AGR (%) Forecast, 2016-2026
  • Figure 6.1 The Global Osteoporosis Drug Market: Revenue ($m) by Leading Regional Markets, 2015, 2020 and 2026
  • Figure 6.2 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2015
  • Figure 6.3 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2020
  • Figure 6.4 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2026
  • Figure 6.5 The US Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.6 The US Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.7 Drivers and Restraints for the US Osteoporosis Market, 2016-2026
  • Figure 6.8 The EU5 Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.9 The EU5 Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.10 Germany Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.11 Germany Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.12 France Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.13 France Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.14 UK Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.15 UK Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.16 Italy Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.17 Italy Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.18 Spain Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.19 Spain Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.20 Japan Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.21 Japan Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.22 The BRIC Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.23 The BRIC Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.24 China Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.25 China Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.26 India Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.27 India Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.28 Russia Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.29 Russia Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.30 Brazil Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.31 Brazil Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.32 South Korea Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.33 South Korea Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.34 RoW Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.35 RoW Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 10.1 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2015
  • Figure 10.2 The Global Osteoporosis Market by Individual Drug Market Share (%), 2015
  • Figure 10.3 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2026
  • Figure 10.4 The Global Osteoporosis Drug Market Therapeutic Class Revenue ($m), 2015, 2020 and 2026
  • Figure 10.5 The Global Osteoporosis Market by Individual Drug Market Share (%), 2026
  • Figure 10.6 The Global Osteoporosis Market by National Market Share (%), 2015
  • Figure 10.7 The Global Osteoporosis Market by National Market Share (%), 2026
  • Figure 10.8 The Global Osteoporosis Market by Revenue ($m), 2015, 2020 and 2026

Companies Listed

  • AbiogenPharma S.p.A
  • Ablynx
  • Actavis
  • Ahn-Gook Pharmaceutical
  • Ajinomoto Pharmaceuticals Co
  • Allergan
  • Almirall
  • Amgen
  • Anda, Inc
  • Apotex Inc
  • Asahi Kasei
  • Astellas
  • AstraZeneca
  • Aurobindo Pharma
  • Aventis
  • Aventis Pharma Ltd
  • Azelon Pharmaceuticals
  • Banner Pharmacaps
  • Banyu
  • Barr Pharmaceuticals
  • Bayer
  • Celltech
  • Chugai Pharmaceutical Co. Ltd
  • Ciba Specialty Chemicals
  • Ciba-Geigy
  • Covington Venture Fund
  • Daiichi Sankyo
  • Dow Jones Industrial Average
  • EffRx Pharmaceuticals
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • Eli Lilly Japan K.K
  • Fermenta Biotech
  • Glaxo Wellcome plc
  • GlaxoSmithKline (GSK)
  • Hoffmann-La Roche (Roche)
  • Jiangsu Hengrui Medicine Co., Ltd
  • LaboratoriosAtral
  • Lacer S.A
  • Ligand Pharmaceuticals
  • Lighthouse Capital Partners
  • Macleods Pharmaceuticals
  • Medis
  • Merck & Co (MSD)
  • Merck Frosst
  • Merck Sharp & Dohme
  • Mylan Pharmaceuticals
  • Nordic Bioscience
  • Novartis
  • Novartis International AG
  • NPS Pharmaceuticals
  • Nycomed
  • Ono Pharma
  • Orchid Healthcare
  • OsteoGeneX
  • Pfizer, Inc
  • Procter & Gamble (P&G)
  • Prospect Venture Partners
  • Qingdao Chia Tai Haier Pharmaceutical Co., Ltd
  • QS Pharma
  • Radius Health Inc.
  • Roche
  • Sandoz
  • Sanofi Pasteur
  • Sanofi S.A
  • Sanofi-Aventis
  • Sanofi-Synthélabo
  • Searle
  • Servier
  • SmithKline Beecham plc
  • Sumitomo Pharma
  • Sun Pharmaceuticals
  • Taisho
  • Taisho Pharmaceutical Holdings
  • Takeda
  • Takeda Pharmaceutical Co., Ltd
  • Tarsa
  • Teva Pharmaceutical Industries
  • UCB
  • Unigene Laboratories
  • Warner Chilcott
  • Wyeth Pharmaceuticals
  • Zosano Pharma

American Society for Bone and Mineral Research (ASBMR)

  • British National Formulary (BNF)
  • Committee to Evaluate Drugs
  • Derwent World Patent Index
  • Duke University Medical Centre
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • EMA's Committee for Medicinal Products for Human Use (CHMP)
  • Food and Drug Administration (FDA)
  • German Federal Joint Committee
  • Harvard College
  • Health Canada
  • HelpAge International
  • Institute for Quality and Efficiency in Health Care (IQWiG)
  • International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
  • International Osteoporosis Foundation (IOF)
  • Japanese Ministry of Health, Labour, and Welfare
  • Korean Federation of Industries
  • Mayo Clinic
  • Ministry of Civil Affairs of China
  • National Health Service (NHS)
  • National Institute for Health and Care Excellence (NICE)
  • National Osteoporosis Foundation (NOF)
  • Pedriatic Investigation Plan (PIP)
  • Paediatric Written Request
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Plaintiffs' Steering Committee
  • Queen Elizabeth Medical Foundation
  • Sandwell General Hospital
  • The Committee for Medicinal Products for Human Use (CHMP)
  • The Committee to Evaluate Drugs (CED)
  • Unified Health System (SUS)
  • The United Nations
  • US Preventive Services Task Force
  • Washington University
  • World Bank
  • World Health Organization (WHO)
Back to Top